These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 3819220)

  • 1. Isotypic and antigenic restriction of the blocking antibody response to ryegrass pollen: correlation of rye group I antigen-specific IgG1 with clinical response.
    Moss RB; Hsu YP; Kwasnicki JM; Sullivan MM; Reid MJ
    J Allergy Clin Immunol; 1987 Feb; 79(2):387-98. PubMed ID: 3819220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IgG subclass antibody markers in grass pollen immunotherapy.
    Moss RB
    N Engl Reg Allergy Proc; 1987; 8(6):409-15. PubMed ID: 3325818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
    Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
    J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased specific immunoglobulin G4 antibodies induced by natural exposure to ambrosia pollen in patients with allergy.
    Ostojić V
    Allergy Asthma Proc; 2016; 37(2):115-20. PubMed ID: 26932170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bahia grass pollen specific IgE is common in seasonal rhinitis patients but has limited cross-reactivity with Ryegrass.
    Davies JM; Bright ML; Rolland JM; O'hehir RE
    Allergy; 2005 Feb; 60(2):251-5. PubMed ID: 15647049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy.
    Ball T; Sperr WR; Valent P; Lidholm J; Spitzauer S; Ebner C; Kraft D; Valenta R
    Eur J Immunol; 1999 Jun; 29(6):2026-36. PubMed ID: 10382766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
    Rossi RE; Monasterolo G
    Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy.
    Shamji MH; Ljørring C; Francis JN; Calderon MA; Larché M; Kimber I; Frew AJ; Ipsen H; Lund K; Würtzen PA; Durham SR
    Allergy; 2012 Feb; 67(2):217-26. PubMed ID: 22077562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allergen-antibody complexes can efficiently prevent seasonal rhinitis and asthma in grass pollen hypersensitive patients. Allergen-antibody complex immunotherapy.
    Machiels JJ; Somville MA; Jacquemin MG; Saint-Remy JM
    Allergy; 1991 Jul; 46(5):335-48. PubMed ID: 1928657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seasonal asthma in northern California: allergic causes and efficacy of immunotherapy.
    Reid MJ; Moss RB; Hsu YP; Kwasnicki JM; Commerford TM; Nelson BL
    J Allergy Clin Immunol; 1986 Oct; 78(4 Pt 1):590-600. PubMed ID: 3771951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of the human immune response to Lolium perenne (rye) pollen and its components, Lol p I and Lol p II (Rye I and Rye II). II. Longitudinal variation of antibody levels in relation to symptomatology and pollen exposure and correction of seasonally elevated antibody levels to basal values.
    Freidhoff LR; Ehrlich-Kautzky E; Meyers DA; Marsh DG
    J Allergy Clin Immunol; 1987 Nov; 80(5):646-55. PubMed ID: 3680810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation.
    Gadermaier E; Staikuniene J; Scheiblhofer S; Thalhamer J; Kundi M; Westritschnig K; Swoboda I; Flicker S; Valenta R
    Allergy; 2011 Sep; 66(9):1174-82. PubMed ID: 21480924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of antibody responses among clinical responders during grass pollen sublingual immunotherapy.
    Baron-Bodo V; Horiot S; Lautrette A; Chabre H; Drucbert AS; Danzé PM; Sénéchal H; Peltre G; Galvain S; Zeldin RK; Horak F; Moingeon P
    Clin Exp Allergy; 2013 Dec; 43(12):1362-73. PubMed ID: 24261946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of IgE and IgG antibody responses of atopic individuals with sensitization to tree and grass pollens.
    Olsen E; Fallang A; Mohapatra SS
    Allergy; 1995 Sep; 50(9):734-40. PubMed ID: 8546268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity.
    Nouri-Aria KT; Wachholz PA; Francis JN; Jacobson MR; Walker SM; Wilcock LK; Staple SQ; Aalberse RC; Till SJ; Durham SR
    J Immunol; 2004 Mar; 172(5):3252-9. PubMed ID: 14978133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
    Bufe A; Ziegler-Kirbach E; Stoeckmann E; Heidemann P; Gehlhar K; Holland-Letz T; Braun W
    Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies.
    Mothes N; Heinzkill M; Drachenberg KJ; Sperr WR; Krauth MT; Majlesi Y; Semper H; Valent P; Niederberger V; Kraft D; Valenta R
    Clin Exp Allergy; 2003 Sep; 33(9):1198-208. PubMed ID: 12956739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ragweed IgE and IgG4 antibody in nasal secretions during immunotherapy.
    Peng Z; Lee HB; Proud D; Naclerio R; Adkinson NF
    Clin Exp Allergy; 1990 Sep; 20(5):571-9. PubMed ID: 2253090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.